GenoMed, Inc. Signs Letter of Intent with Physician Services Company
ST. LOUIS, Sept. 5 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED), ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has signed a letter of intent with Health Services Initiatives, Inc. ("HSI") to introduce its Clinical Outcomes Improvement Program(TM) to physicians in Chicago and parts of the United Kingdom.
Health Services Initiatives is a leading consultant to physicians specializing in developing strategies to protect and raise physician income.
John R. Dolan, FCA (the British equivalent of "CPA"), who is the President and CEO of HSI, stated, "From our discussions, physicians are hugely interested in the promise of the genomic revolution to improve quality and outcomes for their patients. At the same time, they are looking to offset the lowered reimbursement levels and higher expenses caused by managed care. The value proposition of the GenoMed program could not be more timely both in the United States and abroad."
Under the agreement, HSI will introduce and support GenoMed's Clinical Outcomes Improvement Program(TM) to more than 3,000 physicians in Chicago and other target markets across the United States and in parts of the United Kingdom.
GenoMed is currently negotiating agreements with large physician organizations in markets across the United States. GenoMed is also in conversations with international markets as well.
Dr. David Moskowitz, GenoMed's Chairman, said, "We are delighted to have HSI and particularly John Dolan actively involved in our program. Mr. Dolan's breadth of experience, excellent reputation, and credibility with physicians could not be better. Health Services Initiatives is well known in health care circles in Chicago and has long-standing ties to some of the largest hospital and provider systems in the country. In addition, Mr. Dolan's background and relationships in the United Kingdom are a real plus as we push the program to international levels."
Dr. Moskowitz continued, "Through Health Services Initiatives we hope to attain a wide distribution of our Clinical Outcomes Improvement Program(TM). We continue to be excited about the growing number of physician organizations that are embracing GenoMed's mission of preventive molecular medicine, and becoming part of our Clinical Outcomes Improvement Network(TM). We hope in the coming years to capture a significant portion of practicing physicians in the United States and internationally as well."
The Clinical Outcomes Improvement Program(TM) is designed to enable physicians to improve their patients' health dramatically while positively differentiating a physician's practice in the medical marketplace.
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use. A video version of the company's treatment results for chronic kidney failure is available at 216.234.225.2
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer, GenoMed, Inc., +1-1-877-GENOMED, or fax,
+1-314-977-0042, or email: kfischer@genomedics.com
Web site: genomedics.com
. |
